At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 116 enrolled
Drug / intervention
MK-4166 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies
In Brief
A Phase 1 clinical trial evaluating MK-4166 and Pembrolizumab for Solid Tumor. Completed, enrolled 116 participants.
Detailed Summary
This is planned to be a 5-part dose-escalation study to determine the safety and tolerability of MK-4166 monotherapy and MK-4166 plus pembrolizumab combination therapy, and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) of MK-4166 and MK-4166 plus pembrolizumab by defining dose-limiting toxicities (DLTs) in participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionJul 2019
TodayJul 2026
First PostedMay 7, 2014
Enrollment StartJun 27, 2014
Primary CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 12.2 years ago
Interventions
MK-4166biological
Pembrolizumabbiological